Design Therapeutics to present Phase 1/2 DT-216P2 Friedreich’s ataxia trial data May 18

Design Therapeutics, Inc.

Design Therapeutics, Inc.

DSGN

0.00
  • Design Therapeutics set a May 18, 2026 investor webcast to present data from the ongoing Phase 1/2 RESTORE-FA trial of DT-216P2 in Friedreich’s ataxia.
  • The update is positioned as a readout from the trial, a key clinical catalyst for the company’s lead program in a serious genetic disease.
  • No trial outcomes were disclosed in the announcement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Design Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605171600PRIMZONEFULLFEED9721797) on May 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.